Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Systematic Review With Meta-Analysis: The Efficacy and Safety of CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Α Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Review Article: Consensus Statements on Therapeutic Drug Monitoring of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Tumor Necrosis Factor Alpha in Inflammatory Bowel Disease.

Gut
Gastroenterology
1994English

THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

2018English

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Gastroenterologie a Hepatologie
HepatologyGastroenterology
2018English

Infliximab (Anti–Tumor Necrosis Factor Α Antibody)

Archives of Dermatology
2001English

Cost-Of-Illness of Inflammatory Bowel Disease Patients Treated With Anti-Tumour Necrosis Factor: A French Large Single-Centre Experience

United European Gastroenterology Journal
OncologyGastroenterology
2019English

Editorial: Anti-Tumour Necrosis Factor Α Antibodies - Can Efficacy Be Regained?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy